IN8bio to Present at Upcoming Investor and Scientific Conferences in February

Rhea-AI Summary

IN8bio (Nasdaq: INAB) announced CEO and co-founder William Ho will present at two February investor and scientific conferences: Noble Emerging Growth Virtual Equity Conference on Feb 5, 2026 (3:00 p.m. ET, virtual) and IO360° Conference on Feb 12, 2026 (1:20–1:40 p.m. ET) with a plenary on DeltEx DRI and Phase 1/2 GBM results.

Webcast and registration details will be posted in the company’s Events & Presentations section at the corporate website.

News Market Reaction – INAB

+1.53%

6 alerts

+1.53% News Effect

+4.9% Peak in 24 hr 22 min

+$315K Valuation Impact

$21M Market Cap

0.6x Rel. Volume

On the day this news was published, INAB gained 1.53%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $315K to the company's valuation, bringing the market cap to $21M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February.

Conference participation details are as follows:

Noble Emerging Growth Virtual Equity Conference
Date: Thursday, February 5, 2026
Time: 3:00 p.m. ET
Location: Virtual
Investor Registration

IO360° Conference
Date: Thursday, February 12, 2026
Time: 1:20 p.m. – 1:40 p.m. ET
Session: IO Clinical Advancements Plenary
Presentation title: IN8bio’s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM

Additional details, including any available webcast information, will be posted on the Events & Presentations section of the Company’s website at www.in8bio.com.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell product candidates for unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-100, is focused on acute myeloid leukemia, evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The Company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and INB-600, advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Investors & Company Contacts:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact

Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

When will IN8bio (INAB) present at the Noble Emerging Growth Virtual Equity Conference?

IN8bio will present on February 5, 2026 at 3:00 p.m. ET. According to IN8bio, the presentation is virtual and intended for investors, with registration details to be posted on the company's Events & Presentations web page.

What is the topic of IN8bio's presentation at the IO360° Conference on Feb 12, 2026?

The presentation covers DeltEx Drug Resistant Immunotherapy (DRI) and Phase 1/2 GBM results. According to IN8bio, it will be delivered during the IO Clinical Advancements plenary to discuss clinical findings and the DRI approach to solid tumors.

How can investors access IN8bio's webcasts or registration for the February 2026 events?

Investors can find webcast and registration links on the company's Events & Presentations page at www.in8bio.com. According to IN8bio, additional details and any available webcast information will be posted there prior to each conference.

Who will represent IN8bio (INAB) at the February 2026 investor and scientific conferences?

William Ho, CEO and co-founder, will represent IN8bio at both February conferences. According to IN8bio, he will present company strategy and clinical program updates, including a plenary on the DeltEx DRI approach and Phase 1/2 GBM study results.

What time and session is IN8bio scheduled for at the IO360° Conference on February 12, 2026?

IN8bio is scheduled for 1:20 p.m. to 1:40 p.m. ET in the IO Clinical Advancements plenary. According to IN8bio, the slot is a focused 20-minute presentation covering DeltEx DRI and Phase 1/2 data in newly diagnosed GBM.